April 2024

Results presented at ACC.24 showed that overall neutral results were due to directionally opposite effects in patients with reduced vs. preserved left ventricular ejection fraction   Heart failure patients with reduced ejection (HFrEF) had 45% fewer adverse cardiovascular events, whereas patient

Expanded indication for this one-time infusion will provide more patients with a potential period away from their multiple myeloma treatment as early as first relapse Approval is based on results from the Phase 3 CARTITUDE-4 study, in which treatment with CARVYKTI® in 1-3 prior lines of therapy red

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: